Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells (Mahidol University)
- Development stage
- Unknown
- Lead developer
- Mahidol University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are multipotent stromal cells harvested from the umbilical cord matrix. Developed by Mahidol University, this specific cell therapy is being investigated for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE). The cells are administered intravenously following therapeutic hypothermia to leverage their immunomodulatory and neuroprotective properties. WJ-MSCs function primarily through paracrine mechanisms, secreting cytokines and growth factors that reduce neuroinflammation, inhibit apoptosis, and promote endogenous neural repair in the damaged neonatal brain. The SiSTEM-NEO trial evaluates the safety and efficacy of three consecutive daily doses of these cells in infants with moderate to severe HIE.
- Other names
- WJ-MSCsWharton's jelly mesenchymal stem cellsWharton's jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells (Mahidol University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells (Mahidol University).